Lead Sponsor

Astellas Pharma Inc

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•meet the American Rheumatism Association (ARA) 1987 revised criteria for the classification of RA (also referred to as the American College of Rheumatology \[ACR\] criteria);
•being treated with an adequate dose (to the discretion of the local physicians) of either MTX or leflunomide (LEF)or sulfasalazine (SS2) for at least 4 months prior to baseline of which the last 6 weeks before baseline were at a stable dose;
•have active poly-arthritis (i.e. active rheumatoid arthritis as defined in detail in the protocol)

•have been treated with any registered or non-registered investigational drug in the context of a clinical intervention study during the last 3 months before baseline;
•have been treated with TNFα-blockers within a certain period of time (defined for each medication) before baseline;
•have been treated with any DMARD other than MTX, LEF or SS2 during the last month before baseline;
•documented evidence for the presence of clinically severe, unstable, or uncontrollable renal, hepatic, respiratory, hematological, genitourinary, cardiovascular, endocrine, neurological, psychiatric, or other medical illness which would, in the opinion of the investigator, put the patient at safety risk or mask measures of efficacy.

Related studies

NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more

NCT07048197 · Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

NCT06647069 · Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)

NCT07484243 · Rheumatoid Arthritis (RA), Rheumatoid Arthritis-Associated Interstitial Lung Disease, and more

Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis